Gilead has licensed immunization technologies from Hookipa Biotech for use against hepatitis B and HIV. The big biotech is paying $10 million (€8.5 million) upfront and committing to milestones that could exceed $400 million to snag exclusive rights to two technologies in the indications.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,